Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
PHASE4
The purpose of this study is to determine whether the rituximab administrat...
Prediction of Mortality and Morbidity After Hip Fracture Using Monocyte Distribution Width (MDW)
N/A
Hip fracture is a common injury in older adults and is often associated wit...
Status
Recruiting
Location
Laboratory for Research of the Musculoskeletal System
Start Date
2024-12-01
Trial ID
NCT07350785
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
PHASE3
This study evaluates the efficacy and safety of ombitasvir/paritaprevir/rit...
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
PHASE2
This is a dose-ranging study designed to investigate the efficacy and safet...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
PHASE1
The primary purpose is to demonstrate the bioequivalence of naproxen admini...